Inhibikase Therapeutics (IKT) Accumulated Expenses (2020 - 2026)
Inhibikase Therapeutics' Accumulated Expenses was $9.27 million in Q2 2026, up 194.6% from $3.15 million a year earlier and up 124.7% from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Accumulated Expenses (2020 - 2026) Analysis & Trends
At the end of FY2025, Accumulated Expenses at Inhibikase Therapeutics came in at $4.08 million, up 52.3% from FY2024.
- Accumulated Expenses shows a five-year compound annual growth rate of 45.2% (FY2020 to FY2025).
- In earlier years, Accumulated Expenses was $2.68 million in FY2024 (+18.6%), $2.26 million in FY2023 (-5.8%), $2.4 million in FY2022 (-11.7%) and $2.72 million in FY2021 (+329.1%).
- The Q2 2026 figure marks the highest quarterly Accumulated Expenses in data going back to Q4 2020.
- Compared with a year earlier, Accumulated Expenses has increased for ten straight quarters, with growth averaging 57.9% over the last eight quarters.
- The best year-over-year quarter for Accumulated Expenses over five years was Q1 2022 (growth of 469.7%); the worst was Q1 2023 (a decline of 56.4%).
- Per Business Quant data, IKT's Accumulated Expenses in the three quarters before Q2 2026 was $4.12 million (Q1 2026), $4.08 million (Q4 2025) and $3.66 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn |
| 10 | Inhibikase Therapeutics | 336.92 Mn | -248.55 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.27 Mn |
| Mar 31, 2026 | 4.12 Mn |
| Dec 31, 2025 | 4.08 Mn |
| Sep 30, 2025 | 3.66 Mn |
| Jun 30, 2025 | 3.15 Mn |
| Mar 31, 2025 | 3.51 Mn |
| Dec 31, 2024 | 2.68 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 2.03 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | 2.26 Mn |
| Sep 30, 2023 | 1.86 Mn |
| Jun 30, 2023 | 1.83 Mn |
| Mar 31, 2023 | 1.56 Mn |
| Dec 31, 2022 | 2.40 Mn |
| Sep 30, 2022 | 2.29 Mn |
| Jun 30, 2022 | 3.63 Mn |
| Mar 31, 2022 | 3.57 Mn |
| Dec 31, 2021 | 2.72 Mn |
| Sep 30, 2021 | 1.91 Mn |
API Access
Inhibikase Therapeutics Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "accumulated-expenses", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();